PSDV : Summary for pSivida Corp. - Yahoo Finance

U.S. Markets closed

pSivida Corp. (PSDV)


NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
1.74+0.02 (+1.16%)
At close: 4:00 PM EST
People also watch:
ALIMPRANOPXABDSIPGNX
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close1.72
Open1.73
Bid0.72 x 400
Ask3.50 x 3000
Day's Range1.72 - 1.84
52 Week Range1.65 - 5.81
Volume95,095
Avg. Volume175,171
Market Cap59.47M
Beta1.73
PE Ratio (TTM)-2.40
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Capital Cube5 days ago

    ETFs with exposure to pSivida Corp. : December 2, 2016

    Categories: ETFs Yahoo Finance Click here to see latest analysis ETFs with exposure to pSivida Corp. Here are 5 ETFs with the largest exposure to PSDV-US. Comparing the performance and risk of pSivida Corp. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • Capital Cube27 days ago

    ETF’s with exposure to pSivida Corp. : November 10, 2016

    Categories: ETFs Yahoo Finance Click here to see latest analysis ETF’s with exposure to pSivida Corp. Here are 5 ETF’s with the largest exposure to PSDV-US. Comparing the performance and risk of pSivida Corp. with the ETF’s that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • pSivida Corp. :PSDV-US: Earnings Analysis: Q1, 2017 By the Numbers : November 9, 2016
    Capital Cube28 days ago

    pSivida Corp. :PSDV-US: Earnings Analysis: Q1, 2017 By the Numbers : November 9, 2016

    Categories: Yahoo Finance Get free summary analysis pSivida Corp. reports financial results for the quarter ended September 30, 2016. We analyze the earnings along side the following peers of pSivida Corp. – Nektar Therapeutics, Regeneron Pharmaceuticals, Inc., Alimera Sciences, Inc., Abbott Laboratories, Merck & Co., Inc. and Pfizer Inc. (NKTR-US, REGN-US, ALIM-US, ABT-US, MRK-US and PFE-US) that have ... Read more (Read more...)